Talaris Therapeutics, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21	Dec-31-20
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Revenues		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]		55.1	47.7	38.3	30.8	29.1	19.4	11.8
Sales and marketing		22.6	15.3			14.1	3.1
General and administrative				32.5	16.7			17.7
Other selling, general and administrative				5.9				-5.9
Research and development					9.2
Other operating expenses		-84.3	-77.0	-67.6		-42.7	-31.7	-22.7
EBITDA [+]		21.1	20.8	20.7	3.4	10.2	5.5	0.4
EBITDA growth		105.9%	281.5%	4527.5%
Depreciation and amortization		1.0	0.8	0.6	0.6	0.5	0.5	0.4
EBIT [+]		20.1	20.1	20.1	2.8	9.7	5.0	0.0
EBIT growth		106.6%	303.3%
Interest expense, net [+]				0.4	0.0			0.2
Interest expense				0.5				0.4
Interest income					0.1
Other income (expense), net		-83.2	-76.5	-67.5		-43.2	-31.8	-22.5
Pre-tax income		-63.5	-56.8	-47.8	-40.4	-33.8	-27.2	-22.7
Income taxes		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income		-63.5	-56.8	-47.8	-40.4	-33.8	-27.2	-22.7

Basic EPS [+]		($1.67)	($1.64)	($1.83)	($1.97)	($2.82)	($4.01)	($3.45)
Growth		-40.6%	-59.0%	-46.9%
Diluted EPS [+]		($1.67)	($1.64)	($1.83)	($1.97)	($2.82)	($4.01)	($3.45)
Growth		-40.6%	-59.0%	-46.9%

Shares outstanding (basic) [+]		38.0	34.5	26.1	20.5	12.0	6.8	6.6
Growth		216.1%	410.4%	296.8%
Shares outstanding (diluted) [+]		38.0	34.5	26.1	20.5	12.0	6.8	6.6
Growth		216.1%	410.4%	296.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.